Emerging JAK Inhibitors for Patients With Myelofibrosis
Dr Oh discusses emerging JAK inhibitors in the myelofibrosis treatment landscape, highlighting clinical evidence that supports their use.
Case: A 63-Year-Old Man with Myelofibrosis
Clinical Presentation:
- A 63-year-old man recently diagnosed with primary MF and initiated on 10 mg BID ruxolitinib.
- PMH: type 2 diabetes, hypercholesteremia, and hypertension, squamous cell carcinoma (SCC)
Follow up and Clinical Workup at 3 Months:
- Exam: night sweats improved.
- Labs: Hb 7.8 g/dL; Plt 80 x 109/L (previously 135k) stabilized.
- Some spleen reduction.
- Patient receives ~1 unit RBC per month.
Follow up and Clinical Workup at 6 Months:
- Patient reports complaints of fatigue and abdominal pain.
- Labs: Plt 55 x 109/L; Hgb 6.8 g/dL
- Patient now receives 2 units RBC per month.
- Experienced recurrence of SCC.
Epcoritamab Delivers Durable Responses in Anthracycline-Ineligible LBCL
December 12th 2024Fixed-duration, subcutaneous epcoritamab-bysp achieved durable responses with a manageable safety profile in older patients with newly diagnosed large B-cell lymphoma who are not candidates for anthracycline-based therapy.
Read More
Lower Cardiac Risks Found With Second-Generation BTK Inhibitors in B-Cell Hematologic Disorders
December 12th 2024In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, overall cardiac adverse events, and heart failure in patients with B-cell hematologic malignancies.
Read More
